Related Experiment Videos
Heparin-associated thrombocytopenia: case report and prospective study
Australian and New Zealand Journal of Medicine
|February 1, 1980
Summary
Heparin-induced thrombocytopenia (HIT) occurred in 5.4% of patients receiving therapeutic heparin and 1.9% receiving low-dose prophylaxis. Heparin-initiated platelet aggregation is a useful marker for diagnosing HIT.
Area of Science:
- Hematology
- Pharmacology
- Clinical Medicine
Background:
- Heparin is a widely used anticoagulant for thromboembolic disorders.
- Heparin-induced thrombocytopenia (HIT) is a serious adverse effect of heparin therapy.
- Accurate diagnosis and risk assessment of HIT are crucial for patient safety.
Observation:
- A prospective study was conducted to determine the incidence of thrombocytopenia in patients receiving heparin.
- Platelet counts were monitored every second day in 166 patients on therapeutic heparin and 51 on low-dose prophylactic heparin.
- Clinical review and laboratory studies were used to assess causality.
Findings:
- Thrombocytopenia (platelet count < 100 x 10(9)/L) developed in 5.4% of patients on therapeutic heparin and 1.9% on low-dose heparin.
- Heparin was identified as the most likely or contributing cause of thrombocytopenia in 3.0% of patients receiving therapeutic doses.
- Heparin-initiated platelet aggregation in vitro demonstrated utility as a marker for HIT.
Implications:
- The incidence of HIT is significant, particularly with therapeutic heparin doses.
- Early identification and diagnosis of HIT are essential to prevent thrombotic complications.
- Heparin-initiated platelet aggregation assays may aid in the clinical diagnosis of HIT.